IL-ISACA
21.4.2021 15:37:06 CEST | Business Wire | Press release
Emerging technologies are essential to digital transformation and business progress—whether it is blockchain used in supply chains and in the financial industry or artificial intelligence in driving efficiency across sectors. IT professionals seeking to boost their skillset in emerging technologies and ensure their knowledge is up to date can now pursue the Certified in Emerging Technology (CET) certification from global IT professional association and learning organization ISACA.
Established IT professionals, students and recent grads alike can set themselves apart with employers and gain foundational knowledge about the Internet of Things (IoT), artificial intelligence (AI), blockchain and cloud without having prior experience. Along with the recently launched ISACA credential, the Information Technology Certified Associate (ITCA) , the CET certification is unique in offering a vendor-agnostic, hybrid learning model. The CET model features both performance-based and knowledge-based learning—including live labs in a virtual environment—and incorporates a stackable series of certificates.
These certificates, which can be achieved at one’s own pace from anywhere, provide both an examination of each technology and a holistic view of the connections among the emerging technologies, allowing IT professionals to upskill and cross-skill in the following domains:
- Cloud Fundamentals Certificate
- Blockchain Fundamentals Certificate
- IoT Fundamentals Certificate
- Artificial Intelligence Fundamentals Certificate
“It is important for professionals in IT audit, risk, security, governance and privacy to have an understanding of emerging technologies and how they intersect with their work, as well as impact their organizations at a business level,” says David Samuelson, ISACA CEO. “With the new Certified in Emerging Technology certification, ISACA is pleased to offer our global community the tools to gain this knowledge and skillset and continue to take their careers to new heights.”
The CET certification is a good fit for professionals at different levels and job functions—from students and recent graduates wanting to build their résumés, to those already established in roles in governance, risk and compliance; IT audit; network administration; software development; information security; enterprise architecture and business management who want to learn more about emerging technology and how it applies to their roles and organizations.
“Continual up-skilling is a strong signal of professionalism in all IT fields,” said Caitlin McGaw, Principal, Candor McGaw. “Hiring managers are actively looking for people with emerging technology skills. However, since companies are still ramping up these technologies, many professionals have not yet had the chance to gain that experience. Being able to demonstrate the accomplishment of high-quality training and hands-on work with emerging technology will be a substantial competitive advantage for experienced professionals and recent grads alike.”
The CET certification program offers study guides, self-paced training courses, virtual instructor-led training, additional lab packages and exams for each certificate, available at discounted rates to ISACA members. Custom training packages for up-skilling IT teams are also available. Once all four certificate exams are completed, the CET certification is awarded.
This new certification joins an established set of ISACA credentials that have been part of the professional community’s learning journey for years, including Certified Information Systems Auditor (CISA), Certified Information Security Manager (CISM), Certified in Risk and Information Systems Control (CRISC), Certified in the Governance of Enterprise IT (CGEIT), CSX Cybersecurity Practitioner Certification (CSX-P), Certified Data Privacy Solutions Engineer (CDPSE) and ITCA certification.
For more information about the CET certification, visit www.isaca.org/credentialing/cet . More detail about ISACA’s other credentials can be found at www.isaca.org/credentialing , and ISACA publications, audit programs and other resources on emerging tech, including the recently published blockchain framework, are available at www.isaca.org/resources/emerging-technology-resources .
About ISACA
For more than 50 years, ISACA® (www.isaca.org ) equipped individuals with knowledge, credentials, education and community to progress their careers and transform their organizations, and enabled enterprises to train and build quality teams. ISACA is a global professional association and learning organization with more than 150,000 members who work in information security, governance, assurance, risk and privacy, and a presence in 188 countries, including more than 220 chapters worldwide. In 2020, ISACA launched One In Tech, a philanthropic foundation.
Twitter:
www.twitter.com/ISACANews
LinkedIn:
www.linkedin.com/company/isaca
Facebook:
www.facebook.com/ISACAGlobal
Instagram:
www.instagram.com/isacanews
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005669/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
